ReNeuron plc

Stem cell research and development of stem cell therapy, in particular for neurodegenerative diseases

ReNeuron was established in 1997 in order to commercialise technologies that emerged from the Institute of Psychiatry at Kings College London. Merlin Biosciences, UK, was the most important investor. Since August 2005, ReNeuron is relisted on London’s Alternative Investment Market (AIM) under the ticker symbol RENE.L and RENW.L, respectively, after it was delisted in 2003. ReNeuron has entered an agreement with Stem Cells, Inc. to provide Stem Cells, Inc. full access to ReNeuron’s proprietary c-myER(TAM)-technology.

Michael Hunt, CEO
John Sinden, Dr., Founder and CSO

Trevor Jones CBE, Prof.
Michael Hunt
John Sinden, Dr.
Paul Harper, Dr.
Mark Docherty

10 Nugent Rd
Surrey Research Park
Guildford, Surrey
GU2 7AF
UK
Phone: +44-1483-302560
Fax: +44-1483-534864

By means of ReNeuron’s proprietary c-mycER(TAM) technology, which is based on the c-myc gene, ReNeuron was able to generate genetically stable stem cell lines. Proof of principle was tested in a series of validated pre-clinical efficiency models of stroke and Huntington’s Disease. ReNeuron’s stem cell therapy programmes are targeting stroke, type 1 diabetes, retinal diseases, Parkinson’s disease and Huntington’s disease.

ReNeuron offers two neural stem cell lines (ReNcell VM and ReNcell CX) as assay tools for drug discovery.

ReN001 for chronic stroke disability and ReN005 for Huntington’s disease have recently entered late pre-clinical development.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.